CN104379586B - 蛋白激酶抑制剂 - Google Patents

蛋白激酶抑制剂 Download PDF

Info

Publication number
CN104379586B
CN104379586B CN201380028248.2A CN201380028248A CN104379586B CN 104379586 B CN104379586 B CN 104379586B CN 201380028248 A CN201380028248 A CN 201380028248A CN 104379586 B CN104379586 B CN 104379586B
Authority
CN
China
Prior art keywords
mmol
added
compound
reduced pressure
under reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380028248.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104379586A (zh
Inventor
A·劳伦特
Y·罗斯
J·B·加奎斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB005 Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2779184A external-priority patent/CA2779184A1/en
Priority claimed from CA2813299A external-priority patent/CA2813299A1/en
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of CN104379586A publication Critical patent/CN104379586A/zh
Application granted granted Critical
Publication of CN104379586B publication Critical patent/CN104379586B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201380028248.2A 2012-05-31 2013-05-28 蛋白激酶抑制剂 Expired - Fee Related CN104379586B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA2779184A CA2779184A1 (en) 2012-05-31 2012-05-31 Protein kinase inhibitors
CA2,779,184 2012-05-31
CA2813299A CA2813299A1 (en) 2013-04-17 2013-04-17 Protein kinase inhibitors
CA2,813,299 2013-04-17
PCT/CA2013/000513 WO2013177668A1 (en) 2012-05-31 2013-05-28 Protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN104379586A CN104379586A (zh) 2015-02-25
CN104379586B true CN104379586B (zh) 2018-01-16

Family

ID=49672221

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028248.2A Expired - Fee Related CN104379586B (zh) 2012-05-31 2013-05-28 蛋白激酶抑制剂

Country Status (11)

Country Link
US (1) US9796716B2 (enExample)
EP (1) EP2855484A4 (enExample)
JP (1) JP6175495B2 (enExample)
KR (2) KR20190043648A (enExample)
CN (1) CN104379586B (enExample)
BR (1) BR112014029718A2 (enExample)
CA (1) CA2874211A1 (enExample)
HK (1) HK1208460A1 (enExample)
IN (1) IN2014MN02338A (enExample)
RU (1) RU2678767C2 (enExample)
WO (1) WO2013177668A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
CA2834528A1 (en) * 2013-11-26 2015-05-26 Pharmascience Inc. Protein kinase inhibitors
CA2953798C (en) * 2014-07-07 2019-06-11 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
HK1257555A1 (zh) * 2015-05-27 2019-10-25 Gb005, Inc. Tec激酶家族之抑制剂
US10927087B2 (en) 2015-12-07 2021-02-23 Dic Corporation Method for producing polymerizable compound
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
CN109369654A (zh) * 2018-11-20 2019-02-22 山东大学 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
US20250042904A1 (en) * 2021-11-15 2025-02-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Compounds used as src inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390219A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的吡唑并嘧啶类
CN1520298A (zh) * 2001-03-22 2004-08-11 �����ʩ���عɷݹ�˾ 作为治疗剂的吡唑并嘧啶类
CN1523991A (zh) * 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
WO2011046964A2 (en) * 2009-10-12 2011-04-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303363A2 (hu) 1999-09-17 2004-07-28 Abbott Gmbh & Co., Kg Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
CA2363274A1 (en) * 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CA3001152A1 (en) * 2007-03-28 2008-10-09 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
PL2488486T3 (pl) * 2009-10-13 2020-01-31 Ligand Pharmaceuticals Inc. Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania
CN105408334B (zh) * 2013-05-21 2017-10-10 江苏迈度药物研发有限公司 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
CN103787839B (zh) 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390219A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的吡唑并嘧啶类
CN1520298A (zh) * 2001-03-22 2004-08-11 �����ʩ���عɷݹ�˾ 作为治疗剂的吡唑并嘧啶类
CN1523991A (zh) * 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
WO2011046964A2 (en) * 2009-10-12 2011-04-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
WO2013177668A1 (en) 2013-12-05
EP2855484A4 (en) 2015-12-16
HK1208460A1 (en) 2016-03-04
EP2855484A1 (en) 2015-04-08
KR20190043648A (ko) 2019-04-26
JP6175495B2 (ja) 2017-08-02
CA2874211A1 (en) 2013-12-05
KR20150015527A (ko) 2015-02-10
IN2014MN02338A (enExample) 2015-08-14
US20150191473A1 (en) 2015-07-09
KR101972990B1 (ko) 2019-04-26
JP2015518009A (ja) 2015-06-25
BR112014029718A2 (pt) 2017-06-27
US9796716B2 (en) 2017-10-24
CN104379586A (zh) 2015-02-25
RU2014145285A (ru) 2016-07-20
RU2678767C2 (ru) 2019-02-01

Similar Documents

Publication Publication Date Title
CN104379586B (zh) 蛋白激酶抑制剂
CN104718207B (zh) 蛋白激酶抑制剂
JP6321039B2 (ja) 五員かつ六員複素環式化合物並びにその製造方法、医薬品組成物及びその使用
CN115279749B (zh) Shp2抑制剂及其组合物和应用
JP7531595B2 (ja) ピリド［３，４－ｄ］ピリミジン誘導体およびこれを含む治療用薬学組成物
TWI665201B (zh) 吡唑並［１，５－ａ］吡嗪－４－基衍生物
JP6001053B2 (ja) タンパク質キナーゼ阻害剤
US20220017520A1 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
CN108349896A (zh) 作为fgfr抑制剂的杂环化合物
CN113173924A (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
WO2017076355A1 (zh) 嘧啶类衍生物及其用途
CN105315285A (zh) 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
CN109963852A (zh) 新型氧代异喹啉衍生物
WO2017118438A1 (zh) 作为fgfr抑制剂的杂环化合物
AU2016295594A1 (en) Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
JP2022502438A (ja) Ｆｇｆｒ４阻害剤及びその使用
JP6426745B2 (ja) 配座固定されたＰＩ３Ｋ及びｍＴＯＲ阻害剤
WO2021129561A1 (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CA2779184A1 (en) Protein kinase inhibitors
CN111763217B (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
CN114555597A (zh) 异柠檬酸脱氢酶（idh）抑制剂
US20250346604A1 (en) Triazolopyridazine compounds useful as rac1 inhibitors
WO2021180006A1 (zh) 乙烯基取代吡啶类化合物
CN114650991A (zh) 桥环并醛基吡啶衍生物及其应用
KR20070032064A (ko) 포스포티딜이노시톨(ｐｉ) 3-키나제 저해제로서의2,4,6-삼치환 피리미딘 및 암 치료에 있어서의 이의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190729

Address after: American California

Patentee after: GB005 Corporation

Address before: Quebec

Patentee before: PHARMASCIENCE INC.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180116

Termination date: 20200528